Mid-Day Market Update: HCA Healthcare Surges On Upbeat Results; Ardelyx Shares Slide
Midway through trading Tuesday, the Dow traded up 1.54% to 34,486.30 while the NASDAQ rose 1.04% to 14,424.02. The S&P also rose, gaining 1.35% to 4,316.02.
34 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) shares climbed 50.9% to $4.2550.
Mid-Morning Market Update: Markets Open Higher; Philip Morris Posts Mixed Q2 Results
Following the market opening Tuesday, the Dow traded up 1.32% to 34,409.28 while the NASDAQ rose 0.48% to 14,343.85. The S&P also rose, gaining 0.91% to 4,297.39.
Stocks That Hit 52-Week Lows On Tuesday
Before 10 a.m. ET Tuesday, 64 stocks made new 52-week lows.
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 19)
Wedbush Downgrades Ardelyx to Neutral, Announces $3 Price Target
Wedbush analyst Laura Chico downgrades Ardelyx (NASDAQ:ARDX) from Outperform to Neutral and announces $3 price target.
24 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) shares rose 36.9% to $3.86 in pre-market trading after gaining more than 3% on Monday.
Piper Sandler Downgrades Ardelyx to Neutral, Lowers Price Target to $4
Piper Sandler analyst Christopher Raymond downgrades Ardelyx (NASDAQ:ARDX) from Overweight to Neutral and lowers the price target from $14 to $4.